버닝 락 바이오테크 ADR (BNR) 주가 전망: 목표주가, 배당, 최신 뉴스

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.

The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers.

The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc.

to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Burning Rock Biotech Limited는 암 치료 선택 검사를 개발·판매하며 중국 및 미국에서 운영합니다. 회사는 Central Laboratory Business, In-Hospital Business, Pharma Research and Development Services의 세 가지 사업부문으로 구성되어 있습니다.

회사는 NGS 기반의 조직 및 액체생검(liquid biopsy) 암 치료 선택·예후 예측 검사를 제공하며 폐암, 위장관암, 전립선암, 유방암, 림프종, 갑상선암, 대장암, 난소암, 췌장암, 방광암 등 다양한 암종을 대상으로 합니다. 주요 제품으로는 비소세포폐암 환자용 다중 유전자 종양 변이 동시검사 키트인 OncoScreen Focus, 조직샘플용 범용 암 검사 OncoScreen Plus, 액체생검 대응 검사 OncoCompass Plus, NSCLC 대상 ctDNA 기반 검사 OncoCompass Target, MSI 상태 관련 마이크로새틀라이트 좌위 평가 및 위장관계 유전자 변이 검출용 ColonCore 등이 있습니다. 이 밖에 수술 전 ctDNA 검출 및 재발 환자 대상 수술 후 최소잔존질환(MRD) 판정용 CanCatch, 자동 NGS 데이터 분석·보고 해석기인 OncoMaster, Magnis BR-customized 버전 등도 제공하며 실험실 장비 유통과 시약 키트 판매도 병행합니다.

회사는 Myriad Genetics, Inc.와 중국 내 Myriad myChoice 종양검사 in-license를 위한 개발·상용화 계약을 체결했으며 AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, Merck KGaA 등과 임상시험 및 연구 협력을 진행하고 있습니다. 설립은 2014년이며 본사는 중국 광저우에 위치합니다.

• 주소: No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005, China

• 전화번호: 86 20 3403 7871

• 웹사이트: https://www.brbiotech.com

• 섹터: Healthcare

• 산업: Diagnostics & Research

• 직원 수: 667